Abu Qader, a Cornell University freshman, once had a family trip to Afghanistan and saw that the country’s medical care needs attention. He knew and saw people and relatives there fall ill with breast cancer, left undetected and putting their lives in danger. The medical technology company he co-founded now seeks to address gaps in breast cancer treatment through technology.
Image source: Pixabay.com
Many high-tech companies are now vying for attention and pouring investments in this space of medical diagnostics. Mammograms remain the most important diagnostic tool for breast cancer, where suspicious lesions will be tested with a needle biopsy. If the biopsy detects an abnormality, the patient will undergo surgery to remove the lesion. About 90 percent of the time, however, the lesions are found to be benign, rendering the procedure unnecessary.
This is where high-tech diagnostic tools, such as AI based ones, come in and help prevent overscreening and subsequent overtreatment. Machine learning models, for instance, are trained on existing high-risk lesions, considering variables as broad as demographics and family history. They are hoped to correctly predict breast cancer with greater accuracy than most traditional methods.
Image source: Pixabay.com
Callbacks for false positives are said to have been reduced in recent years, thanks to new technology that incorporate 3D data, facilitating the detection of the difference between, say, a breast mass and an overlap of normal tissue. These forms of screening are usually performed in conjunction with conventional mammograms to improve accuracy and reliability of diagnosis.
Matias Campiani is the CEO of Welzwaze, a tech company he co-founded that focuses on the development of AI-based diagnostic and health monitoring solutions, with an emphasis on early breast cancer detection. Learn more about this technology on this page.
No comments:
Post a Comment